The EU regulatory class covering gene, tissue and cell-based medicines.
A regulatory classification (EU ATMP, advanced therapy medicinal product) for cell and gene therapies that require proof of quality, safety, and efficacy before approval. It's a gold-standard designation meaning the therapy has undergone rigorous manufacturing oversight and clinical testing. Clinics advertising "advanced therapy" products are working within regulated frameworks; clinics bypassing this classification are often operating in regulatory grey zones. Ask clinics whether their products hold ATMP designation or equivalent (FDA approval, etc.); if not, ask why and whether they're pursuing it. Lack of regulatory approval signals either early-stage research or intentional circumvention.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估